Clinical Trials Logo
  1. Home
  2. PAH
  3. NCT01320865

Biomarkers in Pulmonary Arterial Hypertension Treated With Nilotinib

PAH Clinical Trial

Clinical Trial Summary

The investigators hypothesize that bone marrow progenitor cells are mobilized into the circulation in PAH, home to the lungs and differentiate into mast cells, which promote vascular remodeling and vasoconstriction through release of renin and chymase. As a corollary to this, the investigators hypothesize that anti cKit tyrosine kinase inhibitor (TKI), nilotinib, provides clinical benefit to patients through inhibition of mast cell progenitor proliferation, mobilization and differentiation. To test this, the investigators will determine if mast cell progenitors and mast cell biomarkers are related to nilotinib clinical response. This will be an ancillary study, part of a placebo-controlled, double-blind multi center clinical trial of nilotinib in pulmonary arterial hypertension.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01320865
Study type Observational
Source The Cleveland Clinic
Contact
Status Withdrawn
Phase N/A
Start date August 2010
Completion date December 2012
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Recruiting NCT04796337 - A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12) Phase 3
Not yet recruiting NCT04309838 - Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmonary Arterial Hypertension
Completed NCT01092897 - Pulmonary Hypertension and Imatinib N/A
Withdrawn NCT02149095 - Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers Phase 1
Terminated NCT04084678 - A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH Phase 3
Completed NCT02276872 - Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years Phase 2
Terminated NCT04053543 - CXA-10 Study in Subjects With Pulmonary Arterial Hypertension Phase 2
Recruiting NCT03626688 - A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients Phase 3
Terminated NCT03449524 - PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH) Phase 2